Literature DB >> 20567236

Selective deletion of adipocytes, but not preadipocytes, by TNF-alpha through C/EBP- and PPARgamma-mediated suppression of NF-kappaB.

Minori Tamai1, Tsuyoshi Shimada, Nobuhiko Hiramatsu, Kunihiro Hayakawa, Maro Okamura, Yasuhiro Tagawa, Shuhei Takahashi, Shotaro Nakajima, Jian Yao, Masanori Kitamura.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is a key regulator of adipose tissue mass, but mechanisms underlying this effect have not been fully elucidated. We found that exposure to TNF-alpha caused a significant decrease in the number of adipocytes, but not preadipocytes. Subsequent experiments revealed that TNF-alpha selectively deleted adipocytes through induction of apoptosis. Following exposure to TNF-alpha, rapid activation of nuclear factor-kappaB (NF-kappaB) was observed only in preadipocytes, but not in adipocytes. Inhibition of NF-kappaB rendered preadipocytes susceptible to TNF-alpha-induced apoptosis, suggesting that different activity of NF-kappaB is the determinant for the distinct apoptotic responses. During adipocyte differentiation, expression and activity of peroxisome proliferator-activated receptor-gamma (PPARgamma) were upregulated. Treatment of preadipocytes with a PPARgamma agonist attenuated NF-kappaB activation and rendered the cells vulnerable to TNF-alpha-induced apoptosis. Conversely, treatment of adipocytes with a PPARgamma antagonist enhanced NF-kappaB activation and conferred resistance to TNF-alpha-induced apoptosis, suggesting involvement of PPARgamma in the suppression of NF-kappaB in adipocytes. We also found that, following differentiation, expression and activity of CCAAT/enhancer binding protein (C/EBP), especially C/EBPalpha and C/EBPbeta, were upregulated in adipocytes. Overexpression of individual C/EBPs significantly inhibited activation of NF-kappaB in preadipocytes. Furthermore, transfection with siRNA for C/EBPalpha or C/EBPbeta enhanced activity of NF-kappaB in adipocytes, suggesting that C/EBP is also involved in the repression of NF-kappaB in adipocytes. These results suggested novel mechanisms by which TNF-alpha selectively deletes adipocytes in the adipose tissue. The C/EBP- and PPARgamma-mediated suppression of NF-kappaB may contribute to TNF-alpha-related loss of adipose tissue mass under certain pathological situations, such as cachexia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567236     DOI: 10.1038/labinvest.2010.118

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

1.  Nutritional interventions for cancer-induced cachexia.

Authors:  Norleena P Gullett; Vera C Mazurak; Gautam Hebbar; Thomas R Ziegler
Journal:  Curr Probl Cancer       Date:  2011 Mar-Apr       Impact factor: 3.187

2.  Stimulation of glycerol kinase in grass carp preadipocytes by EPA.

Authors:  Caixia Lei; Jingjing Tian; Hong Ji
Journal:  Fish Physiol Biochem       Date:  2017-01-05       Impact factor: 2.794

3.  Inhibition of adipogenesis and induction of apoptosis and lipolysis by stem bromelain in 3T3-L1 adipocytes.

Authors:  Sandeep Dave; Naval Jit Kaur; Ravikanth Nanduri; H Kitdorlang Dkhar; Ashwani Kumar; Pawan Gupta
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

4.  Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance.

Authors:  Sachiko Nishimoto; Daiju Fukuda; Yasutomi Higashikuni; Kimie Tanaka; Yoichiro Hirata; Chie Murata; Joo-Ri Kim-Kaneyama; Fukiko Sato; Masahiro Bando; Shusuke Yagi; Takeshi Soeki; Tetsuya Hayashi; Issei Imoto; Hiroshi Sakaue; Michio Shimabukuro; Masataka Sata
Journal:  Sci Adv       Date:  2016-03-25       Impact factor: 14.136

5.  White adipose tissue cells and the progression of cachexia: inflammatory pathways.

Authors:  Rodrigo X Neves; José Cesar Rosa-Neto; Alex S Yamashita; Emidio M Matos-Neto; Daniela M R Riccardi; Fabio S Lira; Miguel L Batista; Marília Seelaender
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-07-07       Impact factor: 12.910

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.